Rituximab drug molecule

Rituximab drug molecule

A617/0222 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 80.0MB

Downloadable file size: 2.3MB

Price image Pricing

Please login to use the price calculator


Caption: Rituximab drug molecule. Computer model showing the secondary structure of the drug rituximab (marketed as MabThera). The primary structure of an oligosaccharide (sugar) is at upper left. Oligosaccharides are necessary for the biological activity of proteins. Rituximab is a monoclonal antibody that binds to CD20 receptors on the surface of B cells (white blood cells), flagging them for destruction by the immune system. It is used to treat rheumatoid arthritis, which is caused by the immune system attacking the body's own tissues. By reducing the number of B cells, symptoms can be reduced. It is also used to treat B cell non-Hodgkin's lymphoma and B cell leukaemia as it clears cancerous B cells from the blood, allowing them to be replaced with healthy cells.

Release details: Model release not required. Property release not required.

Keywords: alpha helix, atom, atoms, auto-immune, autoimmune, b cell leukaemia, ball and stick, ball-and-stick, beta sheet, biochemical, biochemistry, cancer drug, cd20 receptor, chemical, chemistry, chemotherapy, compound, compounds, drug, helices, leukemia, lymphoma, mabthera, medical, medicine, molecular, molecular model, molecule, molecules, monoclonal antibody, non-hodgkin's lymphoma, oligosaccharide, oncology, pharmacological, pharmacology, primary structure, protein, proteins, rheumatoid arthritis, rituximab, secondary structure, sheets, sugar, treatment

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.